PHP85 Advanced Budget Notification (ABN): Is There a Win:Win for Manufacturers and Payers Given the Current Austerity Measures Across the EU  by Mallinson, M.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A467
PHP83
Cost-outCome DesCriPtion of CliniCal PHarmaCist interventions in 
a university teaCHing HosPital
Gallagher J.1, Mc Carthy S.1, Lynch D.2, Woods N.1, Byrne S.1
1University College Cork, Cork, Ireland, 2Cork University Hospital, Cork, Ireland
Objectives: Clinical pharmacist interventions are actions which aim to improve 
a patient’s pharmaceutical care. The primary objective of this study is to esti-
mate the cost savings achieved by clinical pharmacists through the prevention of 
adverse drug events (ADE) in a hospital setting. Previous studies have estimated 
the benefit of these interventions over shorter periods of time and in specific 
hospital areas. This study will encompass a longer time period and a complete 
hospital system. MethOds: This study was a retrospective analysis of a data-
base detailing pharmacist interventions on patient therapies at Cork University 
Hospital. Period examined was from January 2012 to December 2012 inclusive. 
Cost savings were calculated based on the probability that an ADE would have 
occurred in the absence of the proposed pharmacist intervention (Average cost 
of ADE = € 970). Input costs were calculated based on the time required for phar-
macists (n = 17) to enact interventions. One way sensitivity analysis incorporated 
published ranges for intervention time, pharmacist salary and probability an ADE 
would have occurred. Alternative costs for an ADE were also included in analysis. 
Cost savings are from the perspective of the health care institution. Costs are 
presented in 2012 € values. Results: A total of 4,247 interventions were docu-
mented. Base case analysis resulted in net cost benefit of € 590,000 per annum 
and a cost benefit ratio of 10.4:1. Cost savings of € 650,000 were generated and 
the cost of providing the service was estimated at € 60,000. Sensitivity analysis 
resulted in cost benefit ratio varying from 5.2 – 64.8 (minimum – maximum). 
The most prevalent pharmacist intervention was the identification of drug omis-
sions (n= 1820, 42.9%). cOnclusiOns: Cost benefit ratio remained positive in all 
situations examined. This study has added to the body of evidence that clinical 
pharmacist interventions are cost effective over extended time periods and entire 
hospital settings.
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Differential DisCouting: CaPturing tHe value of living longer anD 
Better
Ralston S., Floyd D., Ratcliffe M.
PHMR Associates, London, UK
Objectives: Discounting future cost and health benefits is standard in phar-
macoeconomic evaluations. Using different discount rates for costs and benefits 
remains controversial, although there is a case for lowering the health effect 
discount rate as the general population benefits from better health over a longer 
period of time. The implications of differential discounting on the likely duration 
of health benefits was assessed. MethOds: An extensive literature review sourced 
current discount rates for European countries, including the justification for those 
rates where available. Using a specific example (mifamurtide [Mepact, Takeda] for 
the treatment of osteosarcoma) the time to loss of health benefits for equal and 
differential discount rates using a UK reference case was assessed. Results: 
Like most of Europe, the UK National Institute for Clinical Excellence (NICE) has 
been using a discount rate of 3.5% for both costs and health effects. However, it 
has recently adopted a differential reference case where health effects are sus-
tained over a period of 30 years or more: 1.5% for health effects and 3.5% for costs. 
Taking the example of mifamurtide and using the original rate of 3.5% for health 
effects, all benefit would be discounted away after just 22 years. By adopting the 
lower rate, the effects will not be discounted away until 49 years after treatment. 
In this case, the discount rates used to for mifamurtide are particularly sensitive 
because all costs are borne in the first year, yet benefits of treatment can be over a 
patient’s lifetime. cOnclusiOns: Adopting differential discounting rates reflects 
the potential long-term benefits of new health care technologies. However, most 
European countries, with the exceptions of Belgium, The Netherlands and now 
the UK in specific circumstances, continue to use the same discount rate for costs 
and health effects, thereby potentially undervaluing the long-term benefits cur-
rent and new treatments.
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Objectives: The mature health economies across the EU are severely fiscally 
challenged, and yet manufacturers of innovative medicines are where the legisla-
tion permits expected to give a notifiable ‘warning’ of expected budget impact. A 
survey was undertaken amongst payers to ascertain their real world expectations 
in terms of advanced warning and how realistically a collaborative approach to 
access could be achieved. MethOds: Manufacturers of innovative technologies 
are where legislation permits advised to supply payers and budget holders with 
information that will assist the aforesaid bodies with sufficient information to 
decide on the managed entry of that technology; historically manufacturers are 
in two minds about the value of this process. A study was undertaken with payers 
as to their perceived interest and interaction with manufacturers who willingly 
entered into ABN. Payers at a regional and national level were interviewed to gauge 
their opinions. Results: There appears to be a dichotomy of opinion amongst 
payers as to the value of the legislation; ‘damned if you do, damned if you don’t’, 
however it clearly is in the interest of both parties to work together. Payers value 
the contact and information provision from Manufacturers, Manufactures seek to 
garner the approval of payers. cOnclusiOns: The EU is in the worst economic 
depression since the 1930’s, affordability is the key watchword. New technologies 
need to continue to be presented to payers in a manner which allows them to plan 
for fiscal pressure and service redesign.
Objectives: The study examined: a) the relationship between pharma care and 
health outcomes, b) the influence of expenditure on drugs to the level of expendi-
ture on other forms of care c) the impact of providers on the level of pharma 
expenditure. MethOds: We conducted linear multiple regression analysis with 
pharma expenditure as independent variable, and dependent variables such as 
clinical indicators and expenditure of other categories. Also, we conducted analy-
ses with number of physicians and pharmacists as independent variables and 
pharma expenditure as dependent. Analyses were conducted for all Eurozone 
countries (2003-2011). All tests of statistical significance were two-tailed, and 
p-values of less than 0.05 were considered significant. Results: Increased total 
per capita outpatient pharma expenditure (in US $ PPP’s) by 10% was related to 
increase in life expectancy: a) at birth for men by 0.41% (p= 0.07), b) for men 65+ by 
2.35% (p= 0.004), and c) at birth for women by 0.37% (p= 0.03). Moreover, increased 
public pharma expenditure as a % of total current public expenditure by 10% was 
related to a reduction of public current health expenditure (as a % of GDP) by 
2.8% (p< 0.001). A 10% increase of total pharma expenditure as a % of total cur-
rent health expenditure as a % of GDP, was related to a reduction of total current 
health expenditure as a % of GDP by 3.3% (p= 0.045). Finally, an increase in the 
number of pharmacists/100,000 population by 10% was related to an increase of 
total per capita pharmaceutical expenditure by 0.93% (p= 0.07). cOnclusiOns: 
Overall drug expenditure is positively related to population health and negatively 
connected with the level of total health expenditure, a finding that should influ-
ence political decisions on public insurance coverage. The accuracy of our results 
will be further enhanced by similar research in the future, when longer time 
series data are available.
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Objectives: To characterise pricing dynamics between originator biologics and 
biosimilar products in a number of emerging markets, namely Brazil, China, India, 
Mexico, Russia, South Korea and Turkey. MethOds: Prices for the products con-
cerned were based on calculations of ex-manufacturing prices. Prices at time of 
biosimilar launch and from the most recent time point available were selected for 
the respective biosimilar and originator products, and converted to a price-per-unit 
basis. Average prices were then calculated per brand name, where more than one 
strength or formulation of a product existed. In addition, primary and secondary 
research were utilised to obtain further manufacturer and/or retail-level price data 
where possible. Results: At the time of launch, biosimilar products in emerging 
markets exhibit a manufacturer-level price representing an approximately 30% 
discount, on average, over that of the originator biologic. There are a number of 
exceptions, with evidence that some biosimilar products are priced at a mere 40% 
of the originator at time of launch. The more typical 30% differential appears to 
narrow significantly with time, as evidenced across a number of markets that have 
seen activity in the first generation of biosimilar products (e.g., erythropoietins, 
granulocyte colony-stimulating factor, etc). cOnclusiOns: At time of launch, the 
pricing dynamic between originator biologics and their respective biosimilars in 
emerging markets appears to mimic the scenario which has thus far been observed 
in Europe. However, there are exceptions, with some products associated with sig-
nificantly larger discounts at time of launch in certain emerging markets. Over 
time, there tends to be dramatic price erosion for both originators and biosimilars 
as a function of the original originator price. This erosion is driven by competitive 
entry into the market of subsequent biosimilars, coupled with widespread use of 
tendering in the public markets.
PHP82
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Objectives: The University Hospital of Patras (GPNP) has implemented a series of 
prescription monitoring measures that aim at reducing the hospital’s pharmaceu-
tical expenditure. The objective of this study was to evaluate the results of those 
policies. MethOds: Analysis of the 2011 and 2012 economic data of the GPNP on 
purchase and consumption (in terms of quantity and value) of pharmaceutical prod-
ucts, both in the inpatient and outpatient settings, was conducted. Data on the total 
number of outpatient prescriptions and high-cost drugs were also analyzed. The 
subgroup of high-cost drugs was further investigated, by performing a breakdown 
analysis of the expenditure of high-cost drugs by disease area. Results: The cost 
containment measures implemented by the GPNP (which include, among others, 
the development of guidelines on rationalizing the use of pharmaceutical products, 
and a hospital formulary, which took into consideration both clinical and cost data), 
have resulted in a reduction of the total pharmaceutical consumption by 11.5% 
in 2012 (€ 29.4 million) compared to 2011(€ 33.2 million). Although total outpatient 
prescriptions and the related quantity of pharmaceutical products prescribed were 
increased by 8.1% and 10.5%, respectively, the pharmaceutical cost of outpatient care 
was reduced by almost 28%, indicating a significant increase in the prescription of 
lower cost pharmaceuticals. Indeed, the high-cost hospital medicines prescribed to 
outpatients was reduced by almost 21% in 2012. In the inpatient setting, the total 
expenditure on high-cost hospital medicines was reduced by 12.9%. The expenditure 
on cytostatic drugs, which accounts for more than 70% of the total expenditure 
for high-cost drugs in the inpatient setting, was reduced by almost 10%, while the 
number of patients hospitalized was reduced by only 1.6%. cOnclusiOns: The 
policies implemented by the GPNP were successful in reallocating pharmaceutical 
budget towards more innovative medicines in order to ensure patients’ access to 
new therapies.
